Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 17/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 17/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8578390 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL8577505 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL916345 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL7384483 | 0.90 | SRD5A2 (0.81) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL7384487 | 0.90 | SRD5A2 (0.81) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL917095 | 0.88 | SRD5A2 (1.00) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL918268 | 0.88 | SRD5A1 (0.86) | SRD5A2SRD5A1 | |
| SCHEMBL8931520 | 0.88 | SRD5A1 (0.86) | SRD5A2SRD5A1 | |
| SCHEMBL918267 | 0.88 | SRD5A1 (0.86) | SRD5A2SRD5A1 | |
| SCHEMBL8931551 | 0.88 | SRD5A2 (1.00) | SRD5A2SRD5A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | claimed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | claimed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | claimed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0572165-B1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | claimed |
| EP-0572165-A1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | claimed |
| WO-1993023419-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | disclosed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | disclosed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1734963-A4 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MERCK & CO INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1734963-A2 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1302460-B1 | Indolecarboxylic compounds and their use as pharmaceutical compounds | OREAL (FR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005097127-A2 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6596753-B2 | Effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5 alpha -reductase. These compositions treat androgen | SOCIETE L'OREAL S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| EP-1302460-A1 | Indolecarboxylic compounds and their use as pharmaceutical compounds | L'OREAL (FR) | 2003-04-16 | — | — | EP | disclosed |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | BERNARD BRUNO (FR) | 2003-03-13 | — | — | US | disclosed |
| EP-0964852-B1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | OREAL (FR) | 2003-03-12 | — | — | EP | disclosed |
| US-6448285-B1 | DISORDERS ASSOCIATED WITH OVERACTIVITY OF 5 ALPHA REDUCTASE; ANDROGEN DEPENDENT DISORDERS SUCH AS SEBORRHOEA, ACNE, HIRSUTISM AND/OR ANDROGENIC ALOPECIA | SOCIETE L'OREAL S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-0964852-A1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | L'OREAL (FR) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999012905-A1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | L'OREAL (FR) | 1999-03-18 | — | — | WO | disclosed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5817802-A | IN IONIZING MEDIUM WITH A TRIALKYLSILANE | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5696266-A | HYDROGENATING DELTA-5-STEROIDAL ENELACTAM DISSOLVED IN SOLVENT IN PRESENCE OF RHODIUM CATALYST | MERCK & CO., INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0572165-B1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5527807-A | TREATING ALOPECIA, ACNE, PROSTATE DISORDERS | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5470976-A | Enzyme inhibitors | MERCK & CO., INC. (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1995013815-A1 | COMBINATION METHOD FOR THE TREATMENT OF PATTERNED ALOPECIA | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| EP-0572165-A1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993023419-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023419-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | ADRA1D, ADRB1, AGER | SRD5A2 26/4885SRD5A1 17/4885FNTA 788/4885 |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | SRD5A2 26/4885SRD5A1 17/4885FNTA 788/4885 |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | CYP17A1, SRD5A1, SRD5A2 | SRD5A2 3/4885SRD5A1 2/4885FNTA 797/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | SRD5A2 4/4885SRD5A1 10/4885FNTA 1060/4885 |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | ADRA1D, ADRB1, AGER | SRD5A2 53/4885SRD5A1 37/4885FNTA 961/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | SRD5A2 4/4885SRD5A1 10/4885FNTA 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.